p53 as the main traffic controller of the cell signaling network

Frontiers in Bioscience

Volumn 15, Issue 3, 2010, Pages 1172-1190

  Sebastian, Sinto ^a   Azzariti, Amalia ^a   Silvestris, Nicola ^a   Porcelli, Letizia ^a   Russo, Antonio ^b   Tommasino, Massimo ^c   Paradiso, Angelo ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Apoptosis; Cancer; Cell cycle; Cell signaling; p53; Review

Indexed keywords

PROTEIN P53;

APOPTOSIS; CELL AGING; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETICS; HUMAN; MUTATION; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL AGING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; NEOPLASMS; POLYMORPHISM, GENETIC; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77956639395     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3669     Document Type: Review

References (230)

1. A. B. DeLeo, G. Jay, E. Appella, G.C. Dubois, L.W. Law, L.J. Old: Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A 76, 2420-4 (1979). (Pubitemid 9185501)
2. D. Eliyahu, A. Raz, P. Gruss, D. Givol, M. Oren: Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature 312, 646-9 (1984). (Pubitemid 15218336)
3. S.J. Baker, E.R. Fearon, J.M. Nigro, S.R. Hamilton, A.C. Preisinger, J.M. Jessup, P. vanTuinen, D.H. Ledbetter, D.F. Barker, Y. Nakamura, R. White, B. Vogelstein: Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244, 217-21(1989). (Pubitemid 19110302)
4. V. Graupner, K. Schulze-Osthoff, F. Essmann, R.U. Jänicke: Functional characterization of p53beta and p53gamma, two isoforms of the tumor suppressor p53. Cell Cycle 8, 1238-48 (2009).
5. R. Accardi, W. Dong, A. Smet, R. Cui, A. Hautefeuille, A.S. Gabet, B.S. Sylla, L. Gissmann, P. Hainaut, M. Tommasino: Skin human papillomavirus type 38 alters p53 functions by accumulation of deltaNp73. EMBO Rep 7, 334-340 (2006).
6. A.I. Zaika, N. Slade, S.H. Erster, C. Sansome, T.W. Joseph, M. Pearl, E. Chalas, U.M. Moll: DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 196, 765-80 (2002).
7. J. A. Royds, B. Iacopetta: p53 and disease: when the guardian angel fails. Cell Death Differ 13, 1017-1026 (2006).
8. B. Vogelstein, D. Lane, A. J. Levine: Surfing the p53 network. Nature 408, 307- 310 (2000).
9. L. A. Donehower: The p53-deficient mouse: a model for basic and applied cancer studies. Sem Cancer Biol 7, 269- 278 (1996). (Pubitemid 27182786)
10. E. C. Pietsch, O. Humbey, & M. E. Murphey: Polymorphisms in the p53 pathway. Oncogene 25, 1602- 1611 (2006).
11. O. Lapenko, C. Prives: Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ 13, 951-961 (2006).
12. S. Cawley, S. Bekiranov, H.H. Ng, P. Kapranov, E.A. Sekinger, D. Kampa, A. Piccolboni, V. Sementchenko, J. Cheng, A.J. Williams, R. Wheeler, B. Wong, J. Drenkow, M. Yamanaka, S. Patel, S. Brubaker, H. Tammana, G. Helt, K. Struhl, T.R. Gingeras: Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell 116, 499-509 (2004). (Pubitemid 38264428)
13. C. L. Wei, Q. Wu, V.B. Vega, K.P. Chiu, P. Ng, T. Zhang, A. Shahab, H.C. Yong, Y. Fu, Z. Weng, J. Liu, X.D. Zhao, J.L. Chew, Y.L. Lee, V.A. Kuznetsov, W.K. Sung, L.D. Miller, B. Lim, E.T. Liu, Q. Yu, H.H. Ng, Y. Ruan: A global map of p53 transcriptionfactor binding sites in the human genome. Cell 124, 207-219 (2006). (Pubitemid 43069320)
14. S. Matoba, J.G. Kang, W.D. Patino, A. Wragg, M. Boehm, O. Gavrilova, P.J. Hurley, F. Bunz, P.M. Hwang: p53 regulates mitochondrial respiration. Science 312, 1650- 1653 (2006). (Pubitemid 43902663)
15. K. Bensaad, A. Tsuruta, M.A. Selak, M.N. Vidal, K. Nakano, R. Bartrons, E. Gottlieb, K.H. Vousden: TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107-120 (2006). (Pubitemid 44040989)
16. D. Crighton, S. Wilkinson, J. O'Prey, N. Syed, P. Smith, P.R. Harrison, M. Gasco, O. Garrone, T. Crook, K.M. Ryan: DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 14, 121-134 (2006). (Pubitemid 44040988)
17. S. A. Gatz, L. Wiesmuller: p53 in recombination and repair. Cell Death Differ 13, 1003-1016 (2006).
18. K. Bensaad, K. H. Vousden: Savior and slayer: the two faces of p53. Nature Med 11, 1278-1279 (2005). (Pubitemid 41752901)
19. L. Roger, G. Gadea, P. Roux: Control of cell migration: a tumour suppressor function for p53?. Biol Cell 98, 141-152 (2006). (Pubitemid 43336806)
20. R. M. Kortleverm, P. J. Higgins, R. Bernards: Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nature Cell Biol. 8, 877-884 (2006).
21. J. G. Toeodoro, A. E. Parker, X. Zhu, M. R. Green: p53- mediated inhibition of angiogenesis through upregulation of a collagen prolyl hydroxylase. Science 313, 968-971 (2006). (Pubitemid 44267388)
22. F. Murray-Zmijewski, D. P. Lane, J. C. Bourdon: p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 13, 962-972 (2006).
23. X. Wang, H.Y. Kua, Y. Hu, K. Guo, Q. Zeng, Q. Wu, H.H. Ng, G. Karsenty, B. de Crombrugghe, J. Yeh, B. Li: p53 functions as a negative regulator of osteoblastogenesis, steoblast-dependent osteoclastogenesis, and bone remodeling. J Cell Biol 172, 115-125 (2006). (Pubitemid 43042634)
24. W. Nordstrom, J.M Abrams: Guardian ancestry: fly p53 and damage-inducible apoptosis. Cell Death Differ 7, 1035- 1038 (2000).
25. W.B. Derry, A.P. Putzke, J.H. Rothman: Caenorhabditis elegans p53: role in apoptosis, meiosis, and stress resistance. Science 294, 591-595 (2001). (Pubitemid 32999555)
26. B. Schumacher, K. Hofmann, S. Boulton, A. Gartner: The C. elegans homolog of the p53 tumor suppressor is required for DNA damage-induced apoptosis. Curr Biol 11, 1722-1727 (2001). (Pubitemid 33037787)
27. A.J. Levine, W. Hu, Z. Feng: The P53 pathway: what questions remain to be explored?. Cell Death Differ 13, 1027-1036 (2006).
28. T. Kamijo, S. Bodner, E. van de Kamp, D.H. Randle, C.J. Sherr: Tumor spectrum in ARF-deficient mice. Cancer Res 59, 2217-2222 (1999). (Pubitemid 29217688)
29. L. Moore, S. Venkatachalam, H. Vogel, J.C. Watt, C.L. Wu, H. Steinman, S.N. Jones, L.A. Donehower: Cooperativity of p19ARF, Mdm2, and p53 in murine tumorigenesis. Oncogene 22, 7831-7837 (2003). (Pubitemid 37485542)
30. M.A. Lohrum, R.L. Ludwig, M.H. Kubbutat, M. Hanlon, K.H. Vousden: Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 3, 577-587 (2003). (Pubitemid 36808652)
31. M.A. Christophorou, I. Ringshausen, A.J. Finch, L.B. Swigart, G.I. Evan: The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 443, 214-217 (2006). (Pubitemid 44387609)
32. A. Efeyan, I. Garcia-Cao, D. Herranz, S. Velasco-Miguel, M. Serrano: Policing of oncogene activity by p53. Nature 443, 159-160 (2006).
33. W. Maltzman, L. Czyzyk: UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 4, 1689-1694 (1984). (Pubitemid 14008276)
34. D.P. Lane: Cancer p53, guardian of the genome. Nature 358, 15-16 (1992).
35. J.D. Siliciano, C.E Canman, Y. Taya, K. Sakaguchi, E, Appella, M.B. Kastan: DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 11, 3471-3481 (1997). (Pubitemid 28023968)
36. C. Chao, S. Saito, C.W. Anderson, E. Appella, Y. Xu: Phosphorylation of murine p53 at ser- 8 regulates the p53 responses to DNA damage. Proc Natl Acad Sci USA 97, 11936-11941 (2000).
37. S. Saito, A.A. Goodarzi, Y. Higashimoto, Y. Noda, S.P. Lees-Miller, E. Appella, C.W. Anderson: ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation. J Biol Chem 277, 12491- 12494 (2002). (Pubitemid 34952604)
38. E.U. Kurz, S.P Lees-Miller: DNA damage-induced activation of ATM and ATM- dependent signaling pathways. DNA Repair 3, 889-900 (2004). (Pubitemid 38997931)
39. J. Bartkova, Z. Horejsi, K. Koed, A. Kramer, F. Tort, K. Zieger, P. Guldberg, M. Sehested, J.M. Nesland, C. Lukas, T. Orntoft, J. Lukas, J. Bartek: DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434, 864-870 (2005). (Pubitemid 40558993)
40. V.G. Gorgoulis, L.V. Vassiliou, P. Karakaidos, P. Zacharatos, A. Kotsinas, T. Liloglou, M. Venere, R.A. Ditullio Jr, N.G. Kastrinakis, B. Levy, D. Kletsas, A. Yoneta, M. Herlyn, C. Kittas, T.D. Halazonetis: Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434, 907-913 (2005). (Pubitemid 40559004)
41. A.L. Jackson, L.A. Loeb: The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat Res 477, 7-21 (2001). (Pubitemid 32480184)
42. J. Bartkova, N. Rezaei, M. Liontos, P. Karakaidos, D. Kletsas, N. Issaeva, L.V. Vassiliou, E. Kolettas, K. Niforou, V.C. Zoumpourlis, M. Takaoka, H. Nakagawa, F. Tort, K. Fugger, F. Johansson, M. Sehested, C.L. Andersen, L. Dyrskjot, T. Orntoft, J. Lukas, C. Kittas, T. Helleday, T.D. Halazonetis, J. Bartek, V.G. Gorgoulis: Oncogeneinduced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444, 633- 637 (2006). (Pubitemid 44864442)
43. R. Di Micco, M. Fumagalli, A. Cicalese, S. Piccinin, P. Gasparini, C. Luise, C. Schurra, M. Garre, P.G. Nuciforo, A. Bensimon, R. Maestro, P.G. Pelicci, F. d'Adda di Magagna: Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444, 638- 642 (2006). (Pubitemid 44864443)
44. C. Chao, D. Herr, J. Chun, Y. Xu: Ser18 and 23 phosphorylation is required for p53- ependent apoptosis and tumor suppression. Embo J 25, 2615-2622 (2006). (Pubitemid 44012243)
45. L.A. Donehower, M. Harvey, B.L. Slagle, M.J. McArthur, C.A. Montgomery Jr, J.S. Butel, A. Bradley: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356 215-221 (1992).
46. T. Jacks, L. Remington, B.O. Williams, E.M. Schmitt, S. Halachmi, R.T. Bronson, R.A. Weinberg: Tumor spectrum analysis in p53-mutant mice. Curr Biol 4, 1-7 (1994).
47. D.M. Milne, L.E. Campbell, D.G. Campbell, D.W. Meek: p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1. J Biol Chem 270 5511- 5518 (1995).
48. M.C. Hu, W.R. Qiu, Y.P. Wang: JNK1, JNK2 and JNK3 are p53 N-terminal serine 34 kinases. Oncogene 15, 2277-2287 (1997). (Pubitemid 27496979)
49. S.Y. Fuchs, V. Adler, M.R. Pincus, Z. Ronai: MEKK1/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci USA 95, 10541-10546 (1998). (Pubitemid 28413103)
50. D.V. Bulavin, S. Saito, M.C. Hollander, K. Sakaguchi, C.W Anderson, E. Appella, A.J. Jr Fornace: Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J 18, 6845-6854 (1999).
51. T. Buschmann, O. Potapova, A. Bar-Shira, V.N. Ivanov, S.Y. Fuchs, S. Henderson, V.A. Fried, T. Minamoto, D. Alarcon-Vargas, M.R. Pincus, W.A. Gaarde, N.J. Holbrook, Y. Shiloh, Z. Ronai: Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 tabilization and transcriptional activities in response to stress. Mol Cell Biol 21, 2743-2754 (2001). (Pubitemid 32244919)
52. S.L. Harris, A.J. Levine: The p53 pathway: Positive and negative feedback loops. Oncogene 24, 2899-2908 (2005). (Pubitemid 40638098)
53. S. Ingvarsson, B.I. Sigbjornsdottir, C. Huiping, S.H. Hafsteinsdottir, G. Ragnarsson, R.B. Barkardottir, A. Arason, V. Egilsson, J.T. Bergthorsson: Mutation analysis of the CHK2 gene in breast carcinoma and other cancers. Breast Cancer Res 4, R4 (2002).
54. J. Bartek, J. Lukas: Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3, 421-429 (2003). (Pubitemid 38340288)
55. J. Feng, J. Yan, J. Chen, G. Schlake, Z. Jiang, C.H. Buzin, S.S. Sommer, A. Dritschilo: Absence of somatic ATM missense mutations in 58 mammary carcinomas. Cancer Genet Cytogenet 145, 179-182 (2003). (Pubitemid 36993752)
56. F. Gumy-Pause, P. Wacker, A.P. Sappino: ATM gene and lymphoid malignancies. Leukemia 18, 238-242 (2004). (Pubitemid 38240037)
57. C. Greenman, P. Stephens, R. Smith, G.L. Dalgliesh, C. Hunter, G. Bignell, H. Davies, J. Teague, A. Butler, C. Stevens, S. Edkins, S. O'Meara, I. Vastrik, E.E. Schmidt, T. Avis, S. Barthorpe, G. Bhamra, G. Buck, B. Choudhury, J. Clements, J. Cole, E. Dicks, S. Forbes, K. Gray, K. Halliday, R. Harrison, K. Hills, J. Hinton, A. Jenkinson, D. Jones, A. Menzies, T. Mironenko, J. Perry, K. Raine, D. Richardson, R. Shepherd, A. Small, C. Tofts, J. Varian, T. Webb, S. West, S. Widaa, A. Yates, D.P. Cahill, D.N. Louis, P. Goldstraw, A.G. Nicholson, F. Brasseur, L. Looijenga, B.L. Weber, Y.E. Chiew, A. DeFazio, M.F. Greaves, A.R. Green, P. Campbell, E. Birney, D.F. Easton, G. Chenevix-Trench, M.H. Tan, S.K. Khoo, B.T. Teh, S.T. Yuen, S.Y. Leung, R. Wooster, P.A. Futreal, M.R. Stratton: Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158 (2007). (Pubitemid 46398669)
58. M. Serrano, A.W. Lin, M.E. McCurrach, D. Beach, S.W. Lowe: Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602 (1997). (Pubitemid 27152402)
59. C.J. Sherr. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2, 731-737 (2001). (Pubitemid 33679835)
60. I. Palmero, C. Pantoja, M. Serrano: p19ARF links the tumour suppressor p53 to Ras. Nature 395, 125-126 (1998). (Pubitemid 28425643)
61. E. de Stanchina, M.E. McCurrach, F. Zindy, S.Y. Shieh, G. Ferbeyre, A.V. Samuelson, C. Prives, M.F. Roussel, C.J, Sherr, S.W. Lowe: E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev 12, 2434-2442 (1998). (Pubitemid 28371362)
62. F. Zindy, C.M. Eischen, D.H. Randle, T. Kamijo, J.L. Cleveland, C.J. Sherr, M.F. Roussel: Myc signaling via the ARF tumor suppressor regulates p53- dependent apoptosis and immortalization. Genes Dev 12, 2424- 2433 (1998). (Pubitemid 28371361)
63. N.E. Sharpless: INK4a/ARF: A multifunctional tumor suppressor locus. Mutat Res 576, 22-38 (2005). (Pubitemid 40982680)
64. J. Gil, G. Peters: Regulation of the INK4b-ARF-INK4a tumour suppressor locus: All for one or one for all. Nat Rev Mol Cell Biol 7, 667-677 (2006). (Pubitemid 44268212)
65. K. Inoue, M.F. Roussel, C.J. Sherr: Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. Proc Natl Acad Sci USA 96, 3993-3998 (1999). (Pubitemid 29169024)
66. K. Inoue, R. Wen, J.E. Rehg, M. Adachi, J.L. Cleveland, M.F. Roussel, C.J. Sherr: Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis. Genes Dev 14, 1797-1809 (2000). (Pubitemid 30602998)
67. T. Kamijo, F. Zindy, M.F. Roussel, D.E. Quelle, J.R. Downing, R.A. Ashmun, G. Grosveld, C.J. Sherr: Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91, 649- 659 (1997). (Pubitemid 27513656)
68. T. Kamijo, S. Bodner, E. van de Kamp, D.H. Randle, C.J. Sherr: Tumor spectrum in ARF-deficient mice. Cancer Res 59, 2217-2222 (1999). (Pubitemid 29217688)
69. J.A. Randerson-Moor, M. Harland, S. Williams, D. Cuthbert-Heavens, E. Sheridan, J. Aveyard, K. Sibley, L. Whitaker, M. Knowles, J.N. Bishop, D.T. Bishop: A germline deletion of p14(ARF) but not CDKN2A in a melanomaneural system tumour syndrome family. Hum Mol Genet 10, 55- 62 (2001). (Pubitemid 32051568)
70. H. Rizos, S. Puig, C. Badenas, J. Malvehy, A.P. Darmanian, L. Jimenez, M. Mila, R.F. Kefford: A melanoma-associated germline mutation in exon 1beta inactivates p14ARF. Oncogene 20, 5543-5547 (2001). (Pubitemid 32889492)
71. W.Y. Kim, N.E. Sharpless: The regulation of INK4/ARF in cancer and aging. Cell 127, 265-275 (2006). (Pubitemid 44572384)
72. O. Vafa, M. Wade, S. Kern, M. Beeche, T.K. Pandita, G.M. Hampton, G.M. Wahl: c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 9, 1031-1044 (2002). (Pubitemid 34626672)
73. G. Ferbeyre, E. de Stanchina, A.W. Lin, E. Querido, M.E. McCurrach, G.J. Hannon, S.W. Lowe: Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol 22, 3497-3508 (2002). (Pubitemid 34453988)
74. D.V. Bulavin, O.N. Demidov, S. Saito, P. Kauraniemi, C. Phillips, S.A. Amundson, C. Ambrosino, G. Sauter, A.R. Nebreda, C.W. Anderson, A. Kallioniemi, A.J. Fornace Jr, E. Appella: Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 31, 210-215 (2002).
75. R. Alarcón, C. Koumenis, R.K. Geyer, C.G. Maki, A.J. Giaccia: Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation. Cancer Res 59, 6046-6051 (1999). (Pubitemid 30035618)
76. C. Koumenis, R. Alarcon, E. Hammond, P. Sutphin, W. Hoffman, M. Murphy, J. Derr, Y. Taya, S.W. Lowe, M. Kastan, A. Giaccia: Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol 21, 1297- 1310 (2001). (Pubitemid 32114977)
77. E.M. Hammond, N.C. Denko, M.J. Dorie, R.T. Abraham, A.J. Giaccia: Hypoxia links ATR and p53 through replication arrest. Mol Cell Biol 22, 1834-1843 (2002). (Pubitemid 34174999)
78. Q.A. Khan, R. Agarwal, A. Seidel, H. Frank, K.H. Vousden, A. Dipple: DNA adduct levels associated with p53 induction and delay of MCF-7 cells in S phase after exposure to benzo[g]chrysene dihydrodiol epoxide enantiomers. Mol Carcinog 23, 115-120 (1998). (Pubitemid 28507421)
79. A.A. Sablina, P.M. Chumakov, A.J. Levine, B.P. Kopnin: p53 activation in response to microtubule disruption is mediated by integrin-Erk signalling. Oncogene 20, 899-909 (2001). (Pubitemid 32207107)
80. Z.A. Stewart, L.J. Tang, J.A. Pietenpol: Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner. Oncogene 20, 113-124 (2001). (Pubitemid 32142344)
81. G. Damia, L. Filiberti, F. Vikhanskaya, L. Carrassa, Y. Taya, M. D'incalci, M. Broggini: Cisplatinum and taxol induce different patterns of p53 phosphorylation. Neoplasia 3, 10-16 (2001). (Pubitemid 32201605)
82. K. Webley, J.A. Bond, C.J. Jones, J.P. Blaydes, A. Craig, T. Hupp, D. Wynford-Thomas: Posttranslational modifications of p53 in replicative senescence overlapping but distinct from those induced by DNA damage. Mol Cell Biol 20, 2803-2808 (2000). (Pubitemid 30183499)
83. A.M. Bode, Z. Dong: Post-translational modification of p53 in tumorigenesis. Nature Rev Cancer 4, 793-805 (2004). (Pubitemid 39331151)
84. Y.H. Ou, P.H. Chung, T.P. Sun, S.Y. Shieh: p53 Cterminal phosphorylation by CHK1 and CHK2 participates in the regulation of DNA-damage-induced C-terminal acetylation. Mol Biol Cell 16, 1684-1695 (2005).
85. E.S. Stavridi, N.H Chehab, A. Malikzay, T. D. Halazonetis: Substitutions that compromise the ionizing radiation-induced association of p53 with 14-3-3 proteins also compromise the ability of p53 to induce cell cycle arrest. Cancer Res 61, 7030-7033 (2001). (Pubitemid 32946490)
86. O. Bischof, K. Schwamborn, N. Martin, A. Werner, C. Sustmann, R. Grosschedl, A. Dejean: The E3 SUMO ligase PIASy is a regulator of cellular senescence and apoptosis. Mol Cell 22, 783-794 (2006).
87. V. Di Stefano, S. Soddu, A. Sacchi, G. D'Orazi: HIPK2 contributes to PCAF- ediated acetylation and selective transactivation of p21af1 after nonapoptotic DNA damage. Oncogene 24, 5431-5442 (2005). (Pubitemid 43080087)
88. C.D. Knights, J. Catania, S. Di Giovanni, S. Muratoglu, R. Perez, A. Swartzbeck, A.A. Quong, X. Zhang, T. Beerman, R.G. Pestell, M.L. Avantaggiati: Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J Cell Biol 173, 533-544 (2006). (Pubitemid 43765200)
89. L. Le Cam, L.K. Linares, C. Paul, E. Julien, M. Lacroix, E. Hatchi, R. Triboulet, G. Bossis, A. Shmueli, M.S. Rodriguez, O. Coux, C. Sardet: E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation. Cell 127, 775-788 (2006). (Pubitemid 44716249)
90. K. Sakaguchi, J.E. Herrera, S. Saito, T. Miki, M. Bustin, A. Vassilev, C.W. Anderson, E. Appella: DNA damage activates p53 through a phosphorylationacetylation cascade. Genes Dev 12, 2831-2841 (1998). (Pubitemid 28440142)
91. S. Chuikov, J.K. Kurash, J.R. Wilson, B. Xiao, N. Justin, G.S. Ivanov, K. McKinney, P. Tempst, C. Prives, S.J. Gamblin, N.A. Barlev, D. Reinberg: Regulation of p53 activity through lysine methylation. Nature 432, 353-360 (2004). (Pubitemid 39551664)
92. S. St Clair, L. Giono, S. Varmeh-Ziaie, L. Resnick- Silverman, W.J. Liu, A. Padi, J. Dastidar, A. DaCosta, M. Mattia, J.J. Manfredi: DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter. Mol Cell 16, 725-736 (2004). (Pubitemid 39586531)
93. R.A. Johnson, T.A. Ince, K.W. Scotto: Transcriptional repression by p53 through direct binding to a novel DNA element. J Biol Chem 276, 27716-27720 (2001).
94. A. Mirza, Q. Wu, L. Wang, T. McClanahan, W.R. Bishop, F. Gheyas, W. Ding, B. Hutchins, T. Hockenberry, P. Kirschmeier, J.R. Greene, S. Liu: Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. Oncogene 22, 3645-3654 (2003). (Pubitemid 36765324)
95. H.J. Im, T.A. Craig, M.R. Pittelkow, R. Kumar: Characterization of a novel hexameric repeat DNA sequence in the promoter of the immediate early gene, IEX- 1, that mediates 1alpha, 25-dihydroxyvitamin D(3)- associated IEX-1 gene repression. Oncogene 21, 3706-3714 (2002). (Pubitemid 34620534)
96. A.C. Chun, D.Y. Jin: Transcriptional regulation of mitotic checkpoint gene MAD1 by p53. J Biol Chem 278, 37439-37450 (2003). (Pubitemid 37175264)
97. T.F. Burns, P. Fei, K.A. Scata, D.T Dicker, W.S. El- Deiry. Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol 23, 5556-5571 (2003). (Pubitemid 36951322)
98. V. Golubovskaya, A. Kaur, W. Cance: Cloning and characterization of the promoter region of human focal adhesion kinase gene: nuclear factor kappa B and p53 binding sites. Biochim Biophys Acta 1678, 111-125 (2004). (Pubitemid 38626172)
99. D.W. Zhang, K.T. Jeang, C.G. Lee: p53 negatively regulates the expression of FAT10, a gene upregulated in various cancers. Oncogene 25, 2318-2327 (2006).
100. M. Sachdeva, S. Zhu, F. Wu, H. Wu, V. Walia, S. Kumar, R. Elble, K. Watabe, Y.Y. Mo: p53 represses c- Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A 106, 3207-3212 (2009).
101. N.V. Sankpal, M.W. Willman, T.P. Fleming, J.D. Mayfield, W.E. Gillanders: Transcriptional repression of epithelial cell adhesion molecule contributes to p53 control of breast cancer invasion. Cancer Res 69, 753-757 (2009).
102. S. Sohr, K. Engeland: RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53. Cell Cycle 7, 3448-3460 (2008).
103. M.J. Scian, E.H. Carchman, L. Mohanraj, K.E. Stagliano, M.A. Anderson, D. Deb, B.M. Crane, T. Kiyono, B. Windle, S.P. Deb, S. Deb: Wild-type p53 and p73 negatively regulate expression of proliferation related genes. Oncogene 27, 2583-2593 (2008). (Pubitemid 351550876)
104. F. Alimirah, R. Panchanathan, J. Chen, X. Zhang, S.M. Ho, D. Choubey: Expression of androgen receptor is negatively regulated by p53. Neoplasia 9, 1152-1159 (2007). (Pubitemid 350255362)
105. M. Wu, L.G. Xu, T. Su, Y. Tian, Z. Zhai, H.B. Shu: AMID is a p53-inducible gene downregulated in tumors. Oncogene 23, 6815-6819 (2004). (Pubitemid 39280013)
106. K. Nakano, K.H. Vousden: PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7, 683-694 (2001). (Pubitemid 32706359)
107. G.S. Wu, P. Saftig, C. Peters, W.S. El-Deiry: Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity. Oncogene 16, 2177-2183 (1998). (Pubitemid 28220647)
108. M. Dohn, J. Jiang, X. Chen: Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis. Oncogene 20, 6503-6515 (2001). (Pubitemid 32980275)
109. W.S. el-Deiry, T. Tokino, T. Waldman, J.D. Oliner, V.E. Velculescu, M. Burrell, D.E. Hill, E. Healy, J.L. Rees, S.R. Hamilton, et al: Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 55, 2910-2919 (1995).
110. A. Saramäki, C.M. Banwell, M.J. Campbell, C. Carlberg: Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acids Res 34, 543-554 (2006). (Pubitemid 43240242)
111. E. de Stanchina, E. Querido, M. Narita, R.V. Davuluri, P.P. Pandolfi, G. Ferbeyre, S.W. Lowe: PML is a direct p53 target that modulates p53 effector functions. Mol Cell 13, 523-535 (2004). (Pubitemid 38299380)
112. Y. Kimura, T. Furuhata, T. Urano, K. Hirata, Y. Nakamura, T. Tokino: Genomic structure and chromosomal localization of GML (GPI-anchored molecule-like protein), a gene induced by p53. Genomics 41, 477-480 (1997). (Pubitemid 27194804)
113. C.C. Ng, H. Arakawa, S. Fukuda, H. Kondoh, Y. Nakamura: p53RFP, a p53-inducible RING-finger protein, regulates the stability of p21WAF1. Oncogene 22, 4449- 4458 (2003). (Pubitemid 36897976)
114. S. Xie, H. Wu, Q. Wang, J.P. Cogswell, I. Husain, C. Conn, P. Stambrook, M. Jhanwar-Uniyal, W. Dai: Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway. J Biol Chem 276, 43305-43312 (2001).
115. M. Tan, C.W. Heizmann, K. Guan, B.W. Schafer, Y. Sun: Transcriptional activation of the human S100A2 promoter by wild-type p53. FEBS Lett 445, 265-268 (1999). (Pubitemid 29117224)
116. H. Hermeking, C. Lengauer, K. Polyak, T.C. He, L. Zhang, S. Thiagalingam, K.W. Kinzler, B. Vogelstein: 14- 3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1, 3-11 (1997). (Pubitemid 127376388)
117. C. Duriez, N. Falette, C. Audoynaud, C. Moyret-Lalle, K. Bensaad, S. Courtois, Q. Wang, T. Soussi, A. Puisieux: The human BTG2/TIS21/PC3 gene: genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene. Gene 282, 207-214 (2002). (Pubitemid 34117577)
118. L.W. Ellisen, K.D. Ramsayer, C.M. Johannessen, A. Yang, H. Beppu, K. Minda, J.D. Oliner, F. McKeon, D.A. Haber: REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell 10, 995- 1005 (2002). (Pubitemid 35453821)
119. T.G. Hofmann, A. Möller, H. Sirma, H. Zentgraf, Y. Taya, W. Dröge, H. Will, M.L. Schmitz: Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol 4, 1-10 (2002). (Pubitemid 34071974)
120. G. D'Orazi, B. Cecchinelli, T. Bruno, I. Manni, Y. Higashimoto, S. Saito, M. Gostissa, S. Coen, A. Marchetti, G. Del Sal, G. Piaggio, M. Fanciulli, E. Appella, S. Soddu: Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol 4, 11- 19 (2002).
121. N. Taira, K. Nihira, T. Yamaguchi, Y. Miki, K. Yoshida: DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. Mol Cell 25, 725-738 (2007). (Pubitemid 46341924)
122. K. Oda, H. Arakawa, T. Tanaka, K. Matsuda, C. Tanikawa, T. Mori, H. Nishimori, K. Tamai, T. Tokino, Y. Nakamura, Y. Taya: p53AIP1, a potential mediator of p53- dependent apoptosis, and its regulation by Ser-46- phosphorylated p53. Cell 102, 849-862 (2000).
123. A.M. Karst, D.L. Dai, M. Martinka, G. Li: PUMA expression is significantly reduced in human cutaneous melanomas. Oncogene 241111-241116 (2005).
124. S.J. Ichwan, S. Yamada, P. Sumrejkanchanakij, E. Ibrahim-Auerkari, K. Eto, M.A. Ikeda: Defect in serine 46 phosphorylation of p53 contributes to acquisition of p53 resistance in oral squamous cell carcinoma cells. Oncogene 25, 1216-1224 (2006).
125. L.D. Mayo, Y.R. Seo, M.W. Jackson, M.L. Smith, J. Rivera Guzman, C.K. Korgaonkar, D.B. Donner: Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified. J Biol Chem 280, 25953-25959 (2005). (Pubitemid 41022185)
126. S.M. Sykes, H.S. Mellert, M.A. Holbert, K. Li, R. Marmorstein, W.S. Lane, S.B. McMahon: Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 24, 841-851 (2006). (Pubitemid 44960096)
127. Y. Tang, J. Luo, W. Zhang, W. Gu: Tip60-dependent acetylation of p53 modulates the decision between cellcycle arrest and apoptosis. Mol Cell 24, 827-839 (2006). (Pubitemid 44960094)
128. S. Di Giovanni, C.D. Knights, M. Rao, A. Yakovlev, J. Beers, J. Catania, M.L. Avantaggiati, A. I. Faden: The tumor suppressor protein p53 is required for neurite outgrowth and axon regeneration. EMBO J 25, 4084-4096 (2006). (Pubitemid 44338749)
129. W.S. El-Deiry, S.E. Kern, J.A. Pietenpol, K.W. Kinzler, B. Vogelstein: Definition of a consensus binding site for p53. Nat Genet 1, 45-49 (1992).
130. J.C. Bourdon, V. Deguin-Chambon, J.C. Lelong, P. Dessen, P. May, B. Debuire, E. May: Further characterisation of the p53 responsive elementidentification of newcandidate genes for trans-activation by p53. Oncogene 14, 85-94 (1997). (Pubitemid 27042958)
131. N. Makoto, K.Yoko, M. Hitoshi, I.Kyoji: Direct interaction of p21 cyclindependent kinase inhibitor with the retinoblastoma tumor suppressor protein. Biochem Biophys Res Commun 263, 35- 40 (1999).
132. Y.T. Kim, M. Zhao: Aberrant cell cycle regulation in cervical carcinoma. Yonsei Med J 46, 597-613 (2005). (Pubitemid 41804733)
133. P. Nurse: Universal control mechanism regulating onset of M-phase. Nature 344, 503-508 (1990).
134. X.W. Wang, Q. Zhan, J.D. Coursen, M.A. Khan, H.U. Kontny, L. Yu, M.C. Hollander, P.M. O'Connor, A.J. Fornace Jr, C.C. Harris: GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci U S A 96, 3706-11 (1999). (Pubitemid 29168974)
135. W.R. Taylor, G.R. Stark: Regulation of the G2/M transition by p53. Oncogene 20, 1803-15 (2001). (Pubitemid 32458690)
136. M. Hollstein, D. Sidransky, B. Vogelstein, C.C. Harris: p53 mutations in human cancers. Science 253, 49- 53 (1991). (Pubitemid 21917115)
137. C. deFromentel, T. Soussi: TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 4, 1- 15 (1992).
138. A.J. Levine, J. Momand, C.A. Finlay: The p53 tumour suppressor gene. Nature 351, 453-456 (1991). (Pubitemid 21896613)
139. S. Saito, H. Yamaguchi, Y. Higashimoto, C. Chao, Y. Xu, A.J. Fornace Jr, E. Appella, C.W. Anderson: Phosphorylation site interdependence of human p53 posttranslational modifications in response to stress. J Biol Chem 278, 37536-37544 (2003). (Pubitemid 37175275)
140. H. Vaziri, M.D. West, R.C. Allsopp, T.S. Davison, Y.S. Wu, C.H. Arrowsmith, G.G. Poirier, S Benchimol: ATM-dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the posttranslational activation of p53 protein involving poly(ADP-ribose) polymerase. EMBO J 16, 6018-6033 (1997). (Pubitemid 27427297)
141. X. Wang, K. Ohnishi, A. Takahashi, T, Ohnishi: Poly(ADPribosylation) is required for p53-dependent signal transduction induced by radiation. Oncogene 17, 2819-2825 (1998). (Pubitemid 29010052)
142. G. Bakalkin, T. Yakovleva, G. Selivanova, K.P. Magnusson, L. Szekely, E. Kiseleva, G. Klein, L. Terenius, K.G. Wiman: P53 binds single stranded DNA ends and catalyzes DNA renaturation and strand transfer. Proc Natl Acad Sci USA 91, 413-417 (1994). (Pubitemid 24018715)
143. J. Jayaraman, C. Prives: Activation of p53 sequencespecific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 81, 1021-1029 (1995).
144. S. Lee, B. Elenbaas, A. Levine, J. Griffith: p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 81, 1013-1020 (1995).
145. M. Reed, B. Woelker, P. Wang, Y. Wang, M.E. Anderson, P, Tegtmeyer: The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. Proc Natl Acad Sci USA 92, 9455-9459 (1995).
146. P. Oberosler, P. Hloch, U. Ramsperger, H. Stahl: p53- catalyzed annealing of complementary single-stranded nucleic acids. EMBO J 12, 2389-2396 (1993). (Pubitemid 23194189)
147. D. Jean, D. Gendron, L. Delbecchi, P. Bourgaux: p53- mediated DNA renaturation can mimic strand exchange. Nucleic Acids Res 25, 4004- 4012 (1997). (Pubitemid 27443327)
148. S. Lee, L. Cavallo, J. Griffith: Human p53 binds Holliday junctions strongly and facilitates their cleavage. J Biol Chem 272, 7532-7539 (1997). (Pubitemid 27166469)
149. C. Dudenhöffer, M. Kurth, F. Janus, W. Deppert, L. Wiesmüller: Dissociation of the recombination control and the sequence-specific transactivation function of p53. Mol Cell Biol 18, 5332-5342 (1998). (Pubitemid 28388116)
150. C. Janz, S, Süsse, L, Wiesmüller: p53 and recombination intermediates: role of tetramerization at DNA junctions in complex formation and exonucleolytic degradation. Oncogene 21, 2130-2140 (2002). (Pubitemid 34311367)
151. M. Bakhanashvili: Exonucleolytic proofreading by p53 protein. Eur J Biochem 268, 2047-2054 (2001). (Pubitemid 32852946)
152. N. Albrechtsen, I. Dornreiter, F. Grosse, E. Kim, L. Wiesmuller, W. Deppert: Maintenance of genomic integrity by p53: complementary roles for activated and non-activated p53. Oncogene 18, 7706-7717 (1999). (Pubitemid 30052698)
153. P. Bertrand, Y. Saintigny, B.S. Lopez: p53's double life: transactivationindependent repression of homologous recombination. Trends Genet 20, 235-243 (2004). (Pubitemid 38625681)
154. S. Sengupta, C.C. Harris: p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 6, 44-55 (2005). (Pubitemid 40064898)
155. J.S. Fridman, S.W. Lowe: Control of apoptosis by p53. Oncogene 22, 9030-9040 (2003). (Pubitemid 38121703)
156. M. Selvakumaran, H.K. Lin, T. Miyashita, H.G. Wang, S. Krajewski, J.C. Reed, B. Hoffman, D. Liebermann: Immediate early up-regulation of bax expression by p53 but not TGFb1: A paradigm for distinct apoptotic pathways. Oncogene 9, 1791-1798 (1994). (Pubitemid 24163410)
157. T. Miyashita, S. Krajewski, M. Krajewski, H.G. Wang, H.K. Lin, D.A. Liebermann, B. Hoffman, J.C. Reed: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9, 1799-1805 (1994). (Pubitemid 24163411)
158. D.B. Vesely, B. Hoffman, D. A. Liebermann: Phosphatidylinositol 3-kinase/Akt signaling mediates interleukin-6protection against p53-induced apoptosis in M1 myeloid leukemic cells. Oncogene 13, 1-10 (2006).
159. M. Bennett, K. Macdonald, S.W. Chan, J.P. Luzio, R. Simari, P. Weissberg: Cell surface trafficking of Fas: Arapid mechanism of p53-mediated apoptosis. Science 282, 290-293 (1998). (Pubitemid 28487200)
160. L. Buckbinder, R. Talbott, S. Velascomiguel, I. Takenaka, B. Faha, B.R. Seizinger, N. Kley: Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377, 646-649 (1995).
161. R. Baserga: Oncogenes and the strategy of growth factors. Cell 79, 927- 930 (1994).
162. K. Polyak, Y. Xia, J.L. Zweier, K.W. Kinzler, B.A. Vogelstein: Model for p53-induced apoptosis. Nature 389, 300-305 (1997).
163. R. Faraonio, P. Vergara, D. Di Marzo, M.G. Pierantoni, M. Napolitano, T. Russo, F. Cimino: p53 suppresses the Nrf2-dependent transcription of antioxidant response genes. J Biol Chem 31, 31-37 (2006).
164. U.M. Moll, N. Marchenko, X.K. Zhang: p53 and Nur77/TR3 - Transcription factors that directly target mitochondria for cell death induction. Oncogene 25, 4725- 4743 (2006). (Pubitemid 44187622)
165. T. Shibue, S. Suzuki1, H. Okamoto, H. Yoshida, Y. Ohba, A. Takaoka, T. Taniguchi: Differential contribution of Puma and Noxa in dualregulation of p53-mediated apoptotic pathways. EMBO J 25, 4952-4962 (2006). (Pubitemid 44607039)
166. C. Caelles, A. Helmberg, M. Karin: p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370, 220-223 (1994). (Pubitemid 24236778)
167. N.D. Marchenko, A. Zaika, U.M. Moll: Death signalinduced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem 275, 16202-16212 (2000). (Pubitemid 30366932)
168. P. Dumont, J.I. Leu, A, C, Della Pietra, D.L. George, M. Murphy: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33, 357-365 (2003). (Pubitemid 36278852)
169. G.J. Griffiths, L. Dubrez, C.P. Morgan, N.A. Jones, J. Whitehouse, B.M. Corfe, C. Dive, J.A. Hickman: Cell damage-induced conformational changes of the proapoptotic protein Bak in vivo precede the onset of apoptosis. J Cell Biol 144, 903-914 (1999). (Pubitemid 29238967)
170. M. Mihara, S. Erster, A. Zaika, O. Petrenko, T. Chittenden, P. Pancoska, U.M. Moll: p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11, 577-590 (2003). (Pubitemid 36385115)
171. J.E. Chipuk, T. Kuwana, L. Bouchier-Hayes, N.M. Droin, D.D. Newmeyer, M. Schuler, D.R. Green: Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303, 1010-1014 (2004). (Pubitemid 38209704)
172. G. Matlashewski, P. Lamb, D. Pim, J. Peacock, L. Crawford, S. Benchimol: Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. EMBO J 3, 3257-3262 (1984).
173. D. Wolf, Z. Laver-Rudich, V. Rotter: In vitro expression of human p53 cDNA clones and characterization of the cloned human p53 gene. Mol Cell Biol 5, 1887-1893 (1985). (Pubitemid 15049146)
174. E. Harlow, N.M. Williamson, R. Ralston, D.M. Helfman, T.E. Adams: Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53. Mol Cell Biol 5, 1601-1610 (1985). (Pubitemid 15061718)
175. G. Matlashewski, D. Pim, L. Banks, L. Crawford: Alternative splicing of human p53 transcripts. Oncogene Res 1, 77-85 (1987). (Pubitemid 18041729)
176. V.L. Buchman, P.M. Chumakov, N.N. Ninkina, O.P. Samarina, G.P. Georgiev: A variation in the structure of the protein-coding region of the human p53 gene. Gene 70, 245-252 (1988).
177. S. Ara, P.S. Lee, M.F. Hansen, H. Saya: Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res 18, 4961 (1990). (Pubitemid 20280142)
178. G. Beckman, R. Birgander, A. Själander, N. Saha, P.A. Holmberg, A. Kivelä, L. Beckman: Is p53 polymorphism maintained by natural selection?. Hum Hered 44, 266-270 (1994). (Pubitemid 24229554)
179. L.A. Brooks, J.A. Tidy, B. Gusterson, L. Hiller, J. O'Nions, M. Gasco, M.C. Marin, P.J. Farrell, W.G. Kaelin Jr, T. Crook: Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res 60, 6875-7 (2000). (Pubitemid 32059156)
180. M.C. Marin, C.A. Jost, L.A. Brooks, M.S. Irwin, J. O'Nions, J.A. Tidy, N. James, J.M. McGregor, C.A. Harwood, I.G. Yulug, K.H. Vousden, M.J. Allday, B. Gusterson, S. Ikawa, P.W. Hinds, T. Crook, W.G. Kaelin Jr: A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25, 47-54 (2000). (Pubitemid 30257035)
181. M. Bonafè, S. Salvioli, C. Barbi, M. Mishto, C. Trapassi, C. Gemelli, G. Storci, F. Olivieri, D. Monti, C. Franceschi : p53 codon 72 genotype affects apoptosis by cytosine arabinoside in blood leukocytes. Biochem Biophys Res Commun 299, 539-541 (2002). (Pubitemid 36034578)
182. A. Själander, R. Birgander, G. Hallmans, S. Cajander, P. Lenner, L. Athlin, G. Beckman, L. Beckman: p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17, 1313-1316 (1996).
183. X. Wu, H. Zhao, C.I. Amos, S. Shete, N. Makan, W.K. Hong, F.F. Kadlubar, M.R. Spitz: p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. J Natl Cancer Inst 94, 681-690 (2002). (Pubitemid 34552489)
184. F. Granja, J. Morari, E.C. Morari, L.A. Correa, L.V. Assumpç ão, L.S. Ward: Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. Cancer Lett 210, 151-157 (2004). (Pubitemid 38748685)
185. A. Weston, H.M. Ling-Cawley, N.E. Caporaso, E.D. Bowman, R.N. Hoover, B.F. Trump, C.C. Harris: Determination of the allelic frequencies of an L-myc and a p53 polymorphism in human lung cancer. Carcinogenesis 15, 583-587 (1994). (Pubitemid 24124397)
186. R. Birgander, A. Själander, A. Rannug, A.K. Alexandrie, M.I. Sundberg, J. Seidegård, G. Tornling, G. Beckman, L. Beckman: p53 polymorphisms and haplotypes in lung cancer. Carcinogenesis 16, 2233-2236 (1995).
187. A.N. Rosenthal, A. Ryan, R.M. Al-Jehani, A. Storey, C.A.Harwood, I.J. Jacobs: p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet 352, 871-872 (1998). (Pubitemid 28416721)
188. E. Felley-Bosco, A. Weston, H.M. Cawley, W.P. Bennett, C.C. Harris: Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. Am J Hum Genet 53, 752-759 (1993). (Pubitemid 23304148)
189. X. Li, P. Dumont, A. Della Pietra, C. Shetler, M.E. Murphy: The codon 47 polymorphism in p53 is functionally significant. J Biol Chem 280, 24245-2425 (2005).
190. F. Aguilar, C.C. Harris, T. Sun, M. Hollstein, P. Cerutti: Geographic variation of p53 mutational profile in nonmalignant human liver. Science 264, 1317-1319 (1994). (Pubitemid 24219080)
191. D. Lin, M. Fiscella, P.M. O'Connor, J. Jackman, M. Chen, L.L. Luo, A. Sala, S. Travali, E. Appella, W.E. Mercer: Constitutive expression of B-myb can bypass p53- induced Waf1/Cip1-mediated G1 arrest. Proc Natl Acad Sci U S A 91, 10079-10083 (1994). (Pubitemid 24311952)
192. G.M. Clore, J.G. Omichinski, K. Sakaguchi, N. Zambrano, H. Sakamoto, E. Appella, A. M. Gronenborn: High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science 265, 386-391 (1994). (Pubitemid 24259970)
193. P.D. Jeffrey, S. Gorina, N.P. Pavletich: Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 267, 1498-1502 (1995).
194. T.R. Hupp, D.P. Lane: Allosteric activation of latent p53 tetramers. Curr Biol 4, 865-875 (1994).
195. N. Horikoshi, A. Usheva, J. Chen, A.J. Levine, R. Weinmann, T. Shenk: Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S E1A protein disrupts the association, relieving p53- ediated transcriptional repression. Mol Cell Biol 15, 227- 234 (1995). (Pubitemid 24379919)
196. W. Wang, H. Johansson, T. Kvasnicka, L.O. Farnebo, L. Grimelius: Detection of apoptotic cells and expression of Ki-67 antigen, Bcl-2, p53 oncoproteins in human parathyroid adenoma. APMIS 104, 789-796 (1996). (Pubitemid 26411373)
197. S. Collot-Teixeira, J. Bass, F. Denis, S. Ranger-Rogez: Human tumor suppressor p53 and DNA viruses. Rev Med Virol 14, 301-319 (2004). (Pubitemid 39222464)
198. R. Mahieux, C.A. Pise-Masison, C. Nicot, P. Green, W.W. Hall, J.N. Brady: Inactivation of p53 by HTLV type 1 and HTLV type 2 Tax trans-activators. AIDS Res Hum Retroviruses 16, 1677-1681 (2000).
199. P. Sabbatini, S.K. Chiou, L. Rao, E. White: Modulation of p53-mediated transcriptional repression and apoptosis by the adenovirus E1B 19K protein. Mol Cell Biol 15, 1060-1070 (1995).
200. D. Jiang, A. Srinivasan, G. Lozano, P.D. Robbins: SV40 T antigen abrogates p53-mediated transcriptional activity. Oncogene 8, 2805-2812 (1993). (Pubitemid 23279109)
201. J.A. Mietz, T. Unger, J.M. Huibregtse, P.M. Howley: The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J 11, 5013-5020 (1992). (Pubitemid 23023445)
202. D.P. Lane, L.V. Crawford: T antigen is bound to a host protein in SV40-transformed cells. Nature 278, 261- 263 (1979). (Pubitemid 9129076)
203. D.I. Linzer, W. Maltzman, A.J. Levine: The SV40 A gene product is required for the production of a 54, 000 MW cellular tumor antigen. Virology 98, 308-318 (1979). (Pubitemid 10191211)
204. J.N. Harada, A.J. Berk: p53-Independent and - dependent requirements for E1B-55K in adenovirus type 5 replication. J Virol 73, 5333-5344 (1999). (Pubitemid 29274815)
205. E. Querido, J.G. Teodoro, P.E. Branton: Accumulation of p53 induced by the adenovirus E1A protein requires regions involved in the stimulation of DNA synthesis. J Virol 71, 3526-3533 (1997). (Pubitemid 27172363)
206. J.M. Huibregtse, M. Scheffner, P.M. Howley: A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 10, 4129-4135 (1991). (Pubitemid 21905444)
207. M. Scheffner, T. Takahashi, J.M. Huibregtse, J.D. Minna, P.M. Howley: Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins. J Virol 66, 5100-5105 (1992).
208. I. Malanchi, R. Accardi, F. Diehl, A. Smet, E. Androphy, J. Hoheisel, M. Tommasino: Human papillomavirus type 16 E6 promotes retinoblastoma protein phosphorylation and cell cycle progression. J Virol 78, 13769-71378 (2004).
209. H. Lichtig, M. Algrisi, L.E. Botzer, T. Abadi, Y. Verbitzky, A. Jackman, M. Tommasino, I. Zehbe, L. Sherman: HPV16 E6 natural variants exhibit different activities in functional assays relevant to the carcinogenic potential of E6. Virology 350, 216-227 (2006). (Pubitemid 43850589)
210. Y. Asadurian, H. Kurilin, H. Lichtig, A. Jackman, P. Gonen, M. Tommasino, I. Zehbe, L. Sherman: Activities of human papillomavirus 16 E6 natural variants in human keratinocytes. J Med Virol 79, 1751-1760 (2007). (Pubitemid 47479893)
211. G. Ferbeyre, E. de Stanchina, E. Querido, N. Baptiste, C. Prives, S.W. Lowe: PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 14, 2015- 2027 (2000). (Pubitemid 30637352)
212. W.Q. Jiang, L. Szekely, G. Klein, N. Ringertz: Intranuclear redistribution of SV40T, p53, and PML in a conditionally SV40T-immortalized cell line. Exp Cell Res 229, 289-300 (1996). (Pubitemid 27026919)
213. G.G. Maul, D. Negorev, P. Bell, A.M. Ishov: Review: properties and assembly mechanisms of ND10, PML bodies, or PODs. J Struct Biol 129, 278-287 (2000). (Pubitemid 30481369)
214. M. Nevels, T. Spruss, H. Wolf, T. Dobner: The adenovirus E4orf6 protein contributes to malignant transformation by antagonizing E1A-induced accumulation of the tumor suppressor protein p53. Oncogene 18, 9-17 (1999). (Pubitemid 29060574)
215. B. Terris, V. Baldin, S. Dubois, C. Degott, J.F. Flejou, D. Hénin, A. Dejean: PML nuclear bodies are general targets for inflammation and cell proliferation. Cancer Res 55, 1590-1597 (1995).
216. R.D. Everett, G.G. Maul: HSV-1 IE protein Vmw110 causes redistribution of PML. EMBO J 13, 5062-5069 (1994). (Pubitemid 24341087)
217. S.M. Dilworth: Cell alterations induced by the large Tantigens of SV40 and polyoma virus. Semin Cancer Biol 1, 407-414 (1990).
218. O. Mor, M. Read, M. Fried: p53 in polyoma virus transformed REF52 cells. Oncogene 15, 3113-3119 (1997). (Pubitemid 28043490)
219. M.G. Moule, C.H. Collins, F. McCormick, M. Fried: Role for PP2A in ARF signaling to p53. Proc Natl Acad Sci U S A 101, 14063-14066 (2004). (Pubitemid 39305030)
220. A. Yang, F. McKeon: P63 and P73: P53 mimics, menaces and more. Nat Rev Mol Cell Biol 1, 199-207 (2000).
221. G. Melino, X. Lu, M. Gasco, T. Crook, R.A. Knight: Functional regulation of p73 and p63: development and cancer. Trends Biochem. Sci 28, 663-670 (2003). (Pubitemid 37500901)
222. U.M. Moll, N. Slade: p63 and p73: roles in development and tumor formation. Mol Cancer Res 2, 371- 386 (2004). (Pubitemid 39031071)
223. E.R. Flores, K.Y. Tsai, D. Crowley, S. Sengupta, A. Yang, F. McKeon, T. Jacks: p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416, 560-564 (2002). (Pubitemid 34288861)
224. T. Stiewe, S. Zimmermann, A. Frilling, Esche H, B.M. Pützer: Transactivation deficient DeltaTA-p73 acts as an oncogene. Cancer Res 62, 3598-3602 (2002). (Pubitemid 34728831)
225. J.Y. Yang, W. Xia, M.C. Hu: Ionizing radiation activates expression of FOXO3a, Fas ligand, and Bim, and induces cell apoptosis. Int J Oncol 29, 643-648 (2006).
226. W.M. Chan, W.Y. Siu, A. Lau, R.Y. Poon: How many mutant p53 molecules are needed to inactivate a tetramer?. Mol Cell Biol 24, 3536-3551 (2004). (Pubitemid 38452092)
227. M.P. DeYoung, C.M. Johannessen, C.O. Leong, W. Faquin, J.W. Rocco, L.W. Ellisen: Tumor- specific p73 upregulation mediates p63 dependence in squamous cell carcinoma. Cancer Res 66, 9362-9368 (2006). (Pubitemid 44623630)
228. J.W. Rocco, C.O. Leong, N. Kuperwasser, M.P. DeYoung, L.W. Ellisen: p63 mediates survival in squamous cell carcinoma by suppression of p73- dependent apoptosis. Cancer Cell 9, 45-56 (2006). (Pubitemid 43069510)
229. T.S. Davison, C. Vagner, M. Kaghad, A. Ayed, D. Caput, C.H. Arrowsmith: p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53. J Biol Chem 274, 18709-18714 (1999).
230. T. Stiewe, C.C. Theseling, B.M. Pützer: Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J Biol Chem 277, 14177-14185 (2002). (Pubitemid 34968030)